Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data
Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for sev...
Saved in:
| Published in | PLoS medicine Vol. 11; no. 5; p. e1001638 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
01.05.2014
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods.
Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys.
With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. |
|---|---|
| AbstractList | Background: Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods. Methods and Findings: Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys. Conclusions: With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. Please see later in the article for the Editors' Summary. Please see later in the article for the Editors' Summary. Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods. Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys. With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods.BACKGROUNDYellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods.Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys.METHODS AND FINDINGSGeneralised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys.With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns.CONCLUSIONSWith the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. BackgroundYellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods.Methods and findingsGeneralised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys.ConclusionsWith the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. Background Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods. Methods and Findings Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys. Conclusions With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. Please see later in the article for the Editors' Summary Neil Ferguson and colleagues estimate the disease burden of yellow fever in Africa, as well as the impact of mass vaccination campaigns. Please see later in the article for the Editors' Summary Neil Ferguson and colleagues estimate the disease burden of yellow fever in Africa, as well as the impact of mass vaccination campaigns. Please see later in the article for the Editors' Summary Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods. Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys. With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns. Please see later in the article for the Editors' Summary Yellow fever is a flavivirus infection that is transmitted to people and to non-human primates through the bites of infected mosquitoes. This serious viral disease affects people living in and visiting tropical regions of Africa and Central and South America. In rural areas next to forests, the virus typically causes sporadic cases or even small-scale epidemics (outbreaks) but, if it is introduced into urban areas, it can cause large explosive epidemics that are hard to control. Although many people who contract yellow fever do not develop any symptoms, some have mild flu-like symptoms, and others develop a high fever with jaundice (yellowing of the skin and eyes) or hemorrhaging (bleeding) from the mouth, nose, eyes, or stomach. Half of patients who develop these severe symptoms die. Because of this wide spectrum of symptoms, which overlap with those of other tropical diseases, it is hard to diagnose yellow fever from symptoms alone. However, serological tests that detect antibodies to the virus in the blood can help in diagnosis. There is no specific antiviral treatment for yellow fever but its symptoms can be treated. Eradication of yellow fever is not feasible because of the wildlife reservoir for the virus but there is a safe, affordable, and highly effective vaccine against the disease. Large-scale vaccination efforts during the 1940s, 1950s, and 1960s reduced the yellow fever burden for several decades but, after a period of low vaccination coverage, the number of cases rebounded. In 2005, the Yellow Fever Initiative-a collaboration between the World Health Organization (WHO) and the United Nations Children Fund supported by the Global Alliance for Vaccines and Immunization (GAVI Alliance)-was launched to create a vaccine stockpile for use in epidemics and to implement preventive mass vaccination campaigns in the 12 most affected countries in West Africa. Campaigns have now been implemented in all these countries except Nigeria. However, without an estimate of the current yellow fever burden, it is hard to determine the impact of these campaigns. Here, the researchers use recent yellow fever occurrence data, serological survey data, and improved estimation methods to update estimates of the yellow fever burden and to determine the impact of mass vaccination on this burden. The researchers developed a generalized linear statistical model and used data on the locations where yellow fever was reported between 1987 and 2011 in Africa, force of infection estimates for a limited set of locations where serological surveys were available (the force of infection is the rate at which susceptible individuals acquire a disease), data on vaccination coverage, and demographic and environmental data for their calculations. They estimate that about 130,000 yellow fever cases with fever and jaundice or hemorrhage occurred in Africa in 2013 and that about 78,000 people died from the disease. By evaluating the difference... |
| Audience | Academic |
| Author | Perea, William Van Kerkhove, Maria D. Staples, J. Erin Yactayo, Sergio Garske, Tini Ronveaux, Olivier Ferguson, Neil M. Lewis, Rosamund F. |
| AuthorAffiliation | 2 World Health Organization, Geneva, Switzerland 3 Immunization and Vaccine Development, World Health Organization, Ouagadougou, Burkina Faso 1 MRC Centre for Outbreak Analysis, Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom 4 Ottawa Public Health, Ottawa, Ontario, Canada 5 Arboviral Disease Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America University of Oxford, United Kingdom |
| AuthorAffiliation_xml | – name: University of Oxford, United Kingdom – name: 1 MRC Centre for Outbreak Analysis, Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom – name: 3 Immunization and Vaccine Development, World Health Organization, Ouagadougou, Burkina Faso – name: 5 Arboviral Disease Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America – name: 2 World Health Organization, Geneva, Switzerland – name: 4 Ottawa Public Health, Ottawa, Ontario, Canada |
| Author_xml | – sequence: 1 givenname: Tini surname: Garske fullname: Garske, Tini – sequence: 2 givenname: Maria D. surname: Van Kerkhove fullname: Van Kerkhove, Maria D. – sequence: 3 givenname: Sergio surname: Yactayo fullname: Yactayo, Sergio – sequence: 4 givenname: Olivier surname: Ronveaux fullname: Ronveaux, Olivier – sequence: 5 givenname: Rosamund F. surname: Lewis fullname: Lewis, Rosamund F. – sequence: 6 givenname: J. Erin surname: Staples fullname: Staples, J. Erin – sequence: 7 givenname: William surname: Perea fullname: Perea, William – sequence: 8 givenname: Neil M. surname: Ferguson fullname: Ferguson, Neil M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24800812$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVk1trFDEUxwep2It-A9GAIPqwazK3Tfog1F50oVqwWvApnM2cmU2dTdYkUy-f3sxeZFeKVOZhhjO___8k57Kf7BhrMEkeMzpk2Yi9uradM9AO5zOshoxSVmb8XrLHilwMWDkqdza-d5N9768pTQUV9EGym-acUs7SveTXF2xb-52c4Q06og05qp1WcEhOfdAzCNo0JEyRvOlchYbYmpxoj-CRgKnIeDYHFfroe_CeXIFS2kSRNaR2dkYuujBxCF8X8CU629omurfkBAI8TO7X0Hp8tHofJJ_PTj8dvxucX7wdHx-dDxTPijAQLEfO6ywVRVbyWgAUOatEhiVypkQBWNK65hNVxArkvBgpOmG8yliaVaKciOwgebr0nbfWy1XZvGTRjtKMlz0xXhKVhWs5d_Hi7qe0oOUiYF0jwQWtWpQlcJFjXeUpiJxiIWJCLkQNDErGGUav16ts3SR2RqEJDtot0-0_Rk9lY29kThnjRRYNXqwMnP3WoQ9ypr2KXQKDtlucO-dpXtLiDmialpyxlEf02RJtIN5Cm9rG5KrH5VHGU05HLOupwS1UgwbjSeP41TqGt_jhLXx8Kpxpdavg5ZYgMgF_hAY67-X48uN_sB_uzl5cbbPPN9gpQhum3rZdP7Z-G3yy2co_PVxvTwQOl4By1nuHtVQ6LMY_lkG3klHZr-p65mS_qnK1qlGc_yVe-_9T9hsklT9C |
| CitedBy_id | crossref_primary_10_1016_j_bios_2024_116008 crossref_primary_10_1186_s12879_021_06728_x crossref_primary_10_3390_genes9090425 crossref_primary_10_3389_fgeed_2023_1243731 crossref_primary_10_1007_s00248_024_02382_3 crossref_primary_10_3390_vaccines12060578 crossref_primary_10_1007_s11262_020_01737_5 crossref_primary_10_1111_mve_12794 crossref_primary_10_1016_j_actatropica_2016_09_030 crossref_primary_10_3390_insects15080560 crossref_primary_10_1371_journal_pntd_0006409 crossref_primary_10_5582_bst_2016_01051 crossref_primary_10_1016_j_vaccine_2016_05_057 crossref_primary_10_1093_infdis_jiz375 crossref_primary_10_1093_infdis_jiz374 crossref_primary_10_1038_srep20936 crossref_primary_10_1016_j_antiviral_2016_04_013 crossref_primary_10_1016_j_epidem_2019_100356 crossref_primary_10_1371_journal_pcbi_1007369 crossref_primary_10_1016_j_actatropica_2016_05_005 crossref_primary_10_1186_s13071_017_2559_9 crossref_primary_10_1016_j_semnephrol_2023_151472 crossref_primary_10_3390_jcm10040877 crossref_primary_10_1038_s41541_022_00460_6 crossref_primary_10_3389_fimmu_2020_01836 crossref_primary_10_1371_journal_pone_0214170 crossref_primary_10_1007_s40506_020_00237_2 crossref_primary_10_1128_JVI_01706_16 crossref_primary_10_1016_j_antiviral_2023_105737 crossref_primary_10_1038_s41598_020_59880_w crossref_primary_10_37432_jieph_supp_2021_4_4_03_16 crossref_primary_10_1007_s40475_019_00194_x crossref_primary_10_1371_journal_pntd_0005897 crossref_primary_10_1080_20477724_2023_2290375 crossref_primary_10_1136_bmj_n2239 crossref_primary_10_3390_vaccines13030321 crossref_primary_10_1016_j_jviromet_2015_06_006 crossref_primary_10_1038_s41564_020_0714_0 crossref_primary_10_1016_j_ijid_2016_04_025 crossref_primary_10_1186_s40794_023_00212_x crossref_primary_10_1093_jtm_taab013 crossref_primary_10_1093_jtm_taab015 crossref_primary_10_1038_s41598_020_69759_5 crossref_primary_10_1007_s00103_019_03067_w crossref_primary_10_1111_1365_2664_14031 crossref_primary_10_1016_j_ijid_2019_07_033 crossref_primary_10_1016_j_ijid_2017_05_001 crossref_primary_10_1111_jtm_12171 crossref_primary_10_1371_journal_pntd_0007029 crossref_primary_10_3201_eid2313_170550 crossref_primary_10_1038_s41598_017_02325_8 crossref_primary_10_3389_fmicb_2017_02286 crossref_primary_10_1038_s41598_020_71824_y crossref_primary_10_3389_fmicb_2023_1257024 crossref_primary_10_1016_S1473_3099_16_30513_8 crossref_primary_10_1016_S1473_3099_17_30419_X crossref_primary_10_3390_insects14100802 crossref_primary_10_1016_j_yapd_2017_04_002 crossref_primary_10_1371_journal_pntd_0004709 crossref_primary_10_1038_s41598_017_16231_6 crossref_primary_10_1016_j_xcrm_2024_101655 crossref_primary_10_3389_fviro_2024_1459021 crossref_primary_10_3390_v11100960 crossref_primary_10_1038_s41582_024_01000_7 crossref_primary_10_1371_journal_pntd_0004250 crossref_primary_10_1128_JCM_00827_18 crossref_primary_10_1016_j_vaccine_2017_03_032 crossref_primary_10_1186_s12985_016_0621_4 crossref_primary_10_1016_j_coviro_2019_01_001 crossref_primary_10_1038_s41598_017_00798_1 crossref_primary_10_3390_insects14100810 crossref_primary_10_1016_j_vaccine_2019_04_077 crossref_primary_10_1016_j_vhri_2019_01_004 crossref_primary_10_1186_s13071_020_04374_x crossref_primary_10_1098_rstb_2022_0278 crossref_primary_10_1586_14760584_2015_1083430 crossref_primary_10_1016_j_tmaid_2022_102470 crossref_primary_10_1128_CVI_00209_16 crossref_primary_10_2174_2590277602114010024 crossref_primary_10_3390_vaccines8030492 crossref_primary_10_7554_eLife_08347 crossref_primary_10_1186_s13071_018_2695_x crossref_primary_10_7554_eLife_67635 crossref_primary_10_1016_j_medcle_2016_12_029 crossref_primary_10_1371_journal_pcbi_1007355 crossref_primary_10_1128_JVI_00151_19 crossref_primary_10_1371_journal_pntd_0010594 crossref_primary_10_1007_s11908_017_0566_9 crossref_primary_10_3390_vaccines7040179 crossref_primary_10_3201_eid2210_160818 crossref_primary_10_1111_1462_2920_16174 crossref_primary_10_3390_v17030443 crossref_primary_10_1016_j_jcv_2014_08_030 crossref_primary_10_1111_hsc_13329 crossref_primary_10_3390_insects16010033 crossref_primary_10_12968_pnur_2018_29_Sup6_S3 crossref_primary_10_3347_kjp_2019_57_3_283 crossref_primary_10_1016_j_modpat_2023_100188 crossref_primary_10_3390_vaccines9060574 crossref_primary_10_3390_genes9060291 crossref_primary_10_1038_s41467_021_21199_z crossref_primary_10_1016_S1473_3099_23_00114_7 crossref_primary_10_1002_eji_202250133 crossref_primary_10_3201_eid2207_160469 crossref_primary_10_1186_s12874_021_01477_6 crossref_primary_10_1080_14760584_2019_1698955 crossref_primary_10_1371_journal_pntd_0008549 crossref_primary_10_1016_j_actatropica_2020_105385 crossref_primary_10_1371_journal_pmed_1003523 crossref_primary_10_1371_journal_pntd_0008304 crossref_primary_10_1016_j_chom_2024_07_006 crossref_primary_10_1002_bit_27864 crossref_primary_10_1007_s10875_017_0426_2 crossref_primary_10_1016_j_trac_2022_116735 crossref_primary_10_1098_rsos_220086 crossref_primary_10_1038_s41541_023_00699_7 crossref_primary_10_1371_journal_pone_0262312 crossref_primary_10_1186_s12976_018_0081_1 crossref_primary_10_2139_ssrn_3995293 crossref_primary_10_1080_20008686_2021_1988453 crossref_primary_10_1016_j_coviro_2017_11_004 crossref_primary_10_1093_jme_tjw087 crossref_primary_10_1186_s12889_021_12040_9 crossref_primary_10_1002_jmv_70099 crossref_primary_10_1002_jmv_26978 crossref_primary_10_1186_s12879_021_06856_4 crossref_primary_10_1016_j_medcli_2016_09_008 crossref_primary_10_1016_S1473_3099_19_30323_8 crossref_primary_10_1080_20477724_2019_1678939 crossref_primary_10_1016_j_actatropica_2018_07_008 crossref_primary_10_1017_S0950268818002881 crossref_primary_10_3389_fitd_2024_1369608 crossref_primary_10_1038_sdata_2015_35 crossref_primary_10_1016_S1995_7645_14_60210_8 crossref_primary_10_7554_eLife_55619 crossref_primary_10_1186_s12889_018_5726_9 crossref_primary_10_1098_rstb_2018_0276 crossref_primary_10_1007_s10142_023_01072_6 crossref_primary_10_1080_07391102_2019_1707120 crossref_primary_10_1038_s41467_020_19625_9 crossref_primary_10_1111_tmi_12737 crossref_primary_10_1016_j_pop_2018_05_001 crossref_primary_10_1016_j_vaccine_2024_126423 crossref_primary_10_1056_NEJMoa2407293 crossref_primary_10_7554_eLife_64670 crossref_primary_10_1186_s12879_023_08717_8 crossref_primary_10_7554_eLife_67023 crossref_primary_10_12688_wellcomeopenres_15579_1 crossref_primary_10_3389_fmicb_2024_1458166 crossref_primary_10_1016_j_parepi_2022_e00259 crossref_primary_10_2807_1560_7917_ES_2019_24_4_1800684 crossref_primary_10_3390_v13010013 crossref_primary_10_1371_journal_pntd_0006284 crossref_primary_10_1007_s40506_020_00232_7 crossref_primary_10_3390_vaccines7010011 crossref_primary_10_1186_s12879_022_07407_1 crossref_primary_10_1002_jmv_28700 crossref_primary_10_1371_journal_pntd_0010770 crossref_primary_10_1016_j_vaccine_2019_06_063 crossref_primary_10_1016_j_vaccine_2020_11_022 crossref_primary_10_3390_v15102013 crossref_primary_10_1371_journal_pone_0230748 crossref_primary_10_1186_s12879_018_3440_y crossref_primary_10_3390_v13071383 crossref_primary_10_3390_ijerph15020220 crossref_primary_10_3389_fragi_2021_677907 crossref_primary_10_1128_jvi_01516_23 crossref_primary_10_3390_vaccines10030372 crossref_primary_10_1017_bca_2023_11 crossref_primary_10_1016_S1473_3099_18_30545_0 crossref_primary_10_1016_j_heliyon_2023_e14648 crossref_primary_10_1016_j_vaccine_2019_09_051 crossref_primary_10_1371_journal_pntd_0007806 crossref_primary_10_1080_22221751_2019_1688097 crossref_primary_10_1371_journal_pntd_0006158 crossref_primary_10_1016_j_bbagen_2020_129521 crossref_primary_10_1126_sciadv_abg5033 crossref_primary_10_21055_0370_1069_2019_3_6_13 crossref_primary_10_1093_femspd_ftab017 crossref_primary_10_1371_journal_pgph_0003781 crossref_primary_10_1016_S2214_109X_18_30024_X crossref_primary_10_1016_j_vaccine_2019_01_074 crossref_primary_10_1088_1742_6596_1531_1_012066 crossref_primary_10_1042_ETLS20200334 crossref_primary_10_3390_tropicalmed5030125 crossref_primary_10_1371_journal_pcbi_1012777 crossref_primary_10_1016_j_actatropica_2022_106333 crossref_primary_10_1371_journal_pntd_0005858 crossref_primary_10_1080_22221751_2019_1568180 crossref_primary_10_1016_j_virol_2014_07_050 crossref_primary_10_4269_ajtmh_19_0439 crossref_primary_10_1126_science_aat7115 crossref_primary_10_2147_RMHP_S250930 crossref_primary_10_3389_fneur_2021_634827 crossref_primary_10_1016_j_tim_2018_05_012 crossref_primary_10_1093_inthealth_ihu057 crossref_primary_10_1017_S0007485318000342 crossref_primary_10_3389_fpubh_2018_00241 crossref_primary_10_1056_NEJMp1606997 crossref_primary_10_7717_peerj_6466 crossref_primary_10_1371_journal_pone_0268080 crossref_primary_10_1016_j_jobb_2023_12_003 crossref_primary_10_1080_21645515_2024_2391596 crossref_primary_10_1007_s12250_021_00428_1 crossref_primary_10_1056_NEJMoa1710430 |
| Cites_doi | 10.1016/0035-9203(89)90518-X 10.1016/S0065-308X(05)62006-4 10.1046/j.1365-3156.2001.00790.x 10.4269/ajtmh.1993.48.274 10.1201/b14835 10.4269/ajtmh.1980.29.912 10.1016/0147-9571(90)90521-T 10.1016/S0140-6736(01)07185-9 10.1175/1520-0442(1996)009<0840:AOGMPU>2.0.CO;2 10.1371/journal.pone.0056487 10.2307/2531595 10.1080/014311697217099 10.1371/journal.pntd.0000483 10.4269/ajtmh.2006.74.1078 10.1002/sim.1047 10.1016/S0140-6736(88)91425-0 10.1016/S1473-3099(01)00016-0 10.4269/ajtmh.1998.59.108 10.4269/ajtmh.1998.59.644 10.1214/aos/1176344136 10.1016/S1473-3099(11)70147-5 10.1080/10408360490497474 10.1201/b10905 10.1186/1478-7954-9-1 10.1002/joc.1276 10.1016/j.vaccine.2012.11.035 |
| ContentType | Journal Article |
| Contributor | De La Hoz, Fernando Hutubessy, Raymond Burke, Donald Hansen, Peter M Grenfell, Bryan |
| Contributor_xml | – sequence: 1 givenname: Donald surname: Burke fullname: Burke, Donald – sequence: 2 givenname: Fernando surname: De La Hoz fullname: De La Hoz, Fernando – sequence: 3 givenname: Bryan surname: Grenfell fullname: Grenfell, Bryan – sequence: 4 givenname: Peter M surname: Hansen fullname: Hansen, Peter M – sequence: 5 givenname: Raymond surname: Hutubessy fullname: Hutubessy, Raymond |
| Copyright | COPYRIGHT 2014 Public Library of Science 2014 2014 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Citation: Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, et al. (2014) Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Med 11(5): e1001638. doi:10.1371/journal.pmed.1001638 |
| Copyright_xml | – notice: COPYRIGHT 2014 Public Library of Science – notice: 2014 – notice: 2014 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Citation: Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, et al. (2014) Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Med 11(5): e1001638. doi:10.1371/journal.pmed.1001638 |
| CorporateAuthor | for the Yellow Fever Expert Committee Yellow Fever Expert Committee |
| CorporateAuthor_xml | – name: for the Yellow Fever Expert Committee – name: Yellow Fever Expert Committee |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISN ISR 7X8 7T2 7U9 C1K F1W H94 H95 H97 L.G 5PM DOA CZK |
| DOI | 10.1371/journal.pmed.1001638 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Environmental Sciences and Pollution Management ASFA: Aquatic Sciences and Fisheries Abstracts AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals PLoS Medicine |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional Virology and AIDS Abstracts ASFA: Aquatic Sciences and Fisheries Abstracts AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Geography |
| DocumentTitleAlternate | Yellow Fever Burden in Africa |
| EISSN | 1549-1676 |
| ExternalDocumentID | 1536003869 oai_doaj_org_article_6a894efd42a940e59857899fa1a6181e PMC4011853 A382807138 24800812 10_1371_journal_pmed_1001638 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Africa South America ASW, South America Nigeria |
| GeographicLocations_xml | – name: Africa – name: ASW, South America – name: South America – name: Nigeria |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MR/K010174/1 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAUCC AAWOE AAWTL AAYXX ABDBF ABUWG ACGFO ACIHN ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAWUL BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IOF IOV IPO ISN ISR ITC KQ8 M1P M48 MK0 O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM SV3 TR2 TUS UKHRP WOW XSB YZZ ~8M ADXHL CGR CUY CVF ECM EIF H13 IPNFZ NPM PJZUB PPXIY PV9 RIG RZL WOQ PMFND 7X8 7T2 7U9 C1K F1W H94 H95 H97 L.G PUEGO 5PM - 3V. AAPBV ABPTK ADACO BBAFP BCGST CZK ICW M~E PQEST PQUKI PRINS |
| ID | FETCH-LOGICAL-c835t-914e88f3295368f9aa541d93e6e81c95ae60ff8bc51634857c0b18d3123d96b93 |
| IEDL.DBID | M48 |
| ISSN | 1549-1676 1549-1277 |
| IngestDate | Fri Nov 26 17:13:49 EST 2021 Wed Aug 27 01:26:43 EDT 2025 Thu Aug 21 18:43:12 EDT 2025 Sun Aug 24 04:02:16 EDT 2025 Tue Aug 05 10:55:33 EDT 2025 Tue Jun 17 21:26:38 EDT 2025 Thu Jun 12 23:27:20 EDT 2025 Tue Jun 10 20:46:43 EDT 2025 Fri Jun 27 03:57:16 EDT 2025 Fri Jun 27 03:37:37 EDT 2025 Fri Jun 27 04:04:19 EDT 2025 Thu May 22 21:03:48 EDT 2025 Mon Jul 21 06:05:48 EDT 2025 Thu Apr 24 23:03:32 EDT 2025 Tue Jul 01 01:44:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c835t-914e88f3295368f9aa541d93e6e81c95ae60ff8bc51634857c0b18d3123d96b93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Conceived and designed the experiments: TG MDVK SY WP NMF. Analyzed the data: TG NMF. Wrote the first draft of the manuscript: TG MDVK NMF. Contributed to the writing of the manuscript: TG MDVK SY OR RL JES WP NMF. ICMJE criteria for authorship read and met: TG MDVK SY OR RL JES WP NMF. Agree with manuscript results and conclusions: TG MDVK SY OR RL JES WP NMF. Provided input and advice on the methods: RL WP OR JES SY. Membership of the Yellow Fever Expert Committee is provided in the Acknowledgments. The authors have declared that no competing interests exist. |
| OpenAccessLink | https://doaj.org/article/6a894efd42a940e59857899fa1a6181e |
| PMID | 24800812 |
| PQID | 1522681128 |
| PQPubID | 23479 |
| ParticipantIDs | plos_journals_1536003869 doaj_primary_oai_doaj_org_article_6a894efd42a940e59857899fa1a6181e pubmedcentral_primary_oai_pubmedcentral_nih_gov_4011853 proquest_miscellaneous_1534824605 proquest_miscellaneous_1522681128 gale_infotracmisc_A382807138 gale_infotracgeneralonefile_A382807138 gale_infotracacademiconefile_A382807138 gale_incontextgauss_ISR_A382807138 gale_incontextgauss_ISN_A382807138 gale_incontextgauss_IOV_A382807138 gale_healthsolutions_A382807138 pubmed_primary_24800812 crossref_citationtrail_10_1371_journal_pmed_1001638 crossref_primary_10_1371_journal_pmed_1001638 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-05-01 |
| PublicationDateYYYYMMDD | 2014-05-01 |
| PublicationDate_xml | – month: 05 year: 2014 text: 2014-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco, USA |
| PublicationTitle | PLoS medicine |
| PublicationTitleAlternate | PLoS Med |
| PublicationYear | 2014 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | ref13 A Nasidi (ref16) 1989; 83 SA Omilabu (ref32) 1990; 13 ref14 ref53 EJ Sanders (ref18) 1998; 59 ref55 P Xie (ref39) 1996; 9 ref54 (ref26) 2013; 88 KM De Cock (ref15) 1988; 331 G Schwarz (ref49) 1978; 6 ES Jentes (ref11) 2011; 11 O Tomori (ref2) 2004; 41 JD Poland (ref28) 1981; 59 TP Monath (ref20) 1980; 29 TR Loveland (ref41) 1997; 18 N Nathan (ref17) 2001; 358 ref46 ref47 ref42 RJ Hijmans (ref45) 2005; 25 ref44 ref43 (ref4) 1990; 65 ER DeLong (ref50) 1988; 44 TP Monath (ref7) 1993; 48 LA Lee (ref9) 2013; 31 ref3 ref6 ref5 ref35 ref36 J Thonnon (ref19) 1998; 59 TP Monath (ref1) 2001; 1 M Merlin (ref31) 1986; 79 TF Tsai (ref33) 1987; 65 S Briand (ref12) 2009; 3 GT Werner (ref34) 1985; 65 D Rogers (ref10) 2006; 62 G Heinze (ref48) 2002; 21 AD LaBeaud (ref8) 2011; 9 ref24 I Kleinschmidt (ref38) 2001; 6 ref23 ref25 JP Moreau (ref51) 1999; 92 ref22 ref21 MH Kuniholm (ref30) 2006; 74 T Garske (ref40) 2013; 8 H Coulange Bodilis (ref27) 2011; 104 ref29 JE Dobson (ref37) 2000; 66 (ref52) 2003; 78 |
| References_xml | – volume: 78 start-page: 349 year: 2003 ident: ref52 article-title: Yellow fever vaccine publication-title: Weekly Epidemiological Record – ident: ref5 – volume: 83 start-page: 401 year: 1989 ident: ref16 article-title: Urban yellow fever epidemic in western Nigeria, 1987 publication-title: Trans R Soc Trop Med Hyg doi: 10.1016/0035-9203(89)90518-X – volume: 62 start-page: 181 year: 2006 ident: ref10 article-title: The global distribution of yellow fever and dengue publication-title: Adv Parasit doi: 10.1016/S0065-308X(05)62006-4 – ident: ref43 – ident: ref24 – volume: 88 start-page: 269 year: 2013 ident: ref26 article-title: Vaccines and vaccination against yellow fever. WHO Position Paper - June 2013 publication-title: Weekly Epidemiological Record – volume: 6 start-page: 779 year: 2001 ident: ref38 article-title: An empirical malaria distribution map for West Africa publication-title: Trop Med Int Health doi: 10.1046/j.1365-3156.2001.00790.x – volume: 48 start-page: 274 year: 1993 ident: ref7 article-title: Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1993.48.274 – ident: ref47 doi: 10.1201/b14835 – ident: ref53 – volume: 29 start-page: 912 year: 1980 ident: ref20 article-title: Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1980.29.912 – ident: ref13 – volume: 13 start-page: 95 year: 1990 ident: ref32 article-title: Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria publication-title: Comp Immunol Microbiol Infect Dis doi: 10.1016/0147-9571(90)90521-T – volume: 65 start-page: 91 year: 1985 ident: ref34 article-title: [Prevalence of yellow fever antibodies in north Zaire] publication-title: Annales de la Societe belge de medecine tropicale – volume: 79 start-page: 199 year: 1986 ident: ref31 article-title: [Evaluation of immunological and entomotological indices of yellow fever in Pointe-Noire, People's Republic of Congo] publication-title: Bulletin de la Société de pathologie exotique – ident: ref36 – ident: ref6 – volume: 65 start-page: 855 year: 1987 ident: ref33 article-title: Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984 publication-title: Bull World Health Organ – volume: 104 start-page: 260 year: 2011 ident: ref27 article-title: [Long term persistence of yellow fever neutralising antibodies in elderly persons] publication-title: Bull Soc Pathol Exot – ident: ref44 – ident: ref23 – volume: 59 start-page: 895 year: 1981 ident: ref28 article-title: Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine publication-title: Bull World Health Organ – volume: 358 start-page: 2129 year: 2001 ident: ref17 article-title: Shortage of vaccines during a yellow fever outbreak in Guinea publication-title: Lancet doi: 10.1016/S0140-6736(01)07185-9 – volume: 9 start-page: 840 year: 1996 ident: ref39 article-title: Analyses of global monthly precipitation using gauge observations, satellite estimates, and numerical model predictions publication-title: J Climate doi: 10.1175/1520-0442(1996)009<0840:AOGMPU>2.0.CO;2 – ident: ref54 – volume: 8 start-page: e56487 year: 2013 ident: ref40 article-title: Estimating air temperature and its influence on malaria transmission across Africa publication-title: PLoS ONE doi: 10.1371/journal.pone.0056487 – volume: 44 start-page: 837 year: 1988 ident: ref50 article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach publication-title: Biometrics doi: 10.2307/2531595 – ident: ref3 – volume: 18 start-page: 3289 year: 1997 ident: ref41 article-title: The IGBP-DIS global 1 km land cover data set, DISCover: first results publication-title: Int J Remote Sens doi: 10.1080/014311697217099 – volume: 65 start-page: 213 year: 1990 ident: ref4 article-title: Yellow fever in 1988 publication-title: Weekly Epidemiological Record – volume: 3 start-page: e483 year: 2009 ident: ref12 article-title: Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0000483 – volume: 74 start-page: 1078 year: 2006 ident: ref30 article-title: Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2006.74.1078 – ident: ref29 – volume: 21 start-page: 2409 year: 2002 ident: ref48 article-title: A solution to the problem of separation in logistic regression publication-title: Stat in Med doi: 10.1002/sim.1047 – ident: ref22 – ident: ref25 – volume: 331 start-page: 630 year: 1988 ident: ref15 article-title: Epidemic yellow fever in Eastern Nigeria, 1986 publication-title: Lancet doi: 10.1016/S0140-6736(88)91425-0 – volume: 1 start-page: 11 year: 2001 ident: ref1 article-title: Yellow fever: an update publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(01)00016-0 – volume: 59 start-page: 108 year: 1998 ident: ref19 article-title: Re-emergence of yellow fever in Senegal in 1995 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1998.59.108 – volume: 59 start-page: 644 year: 1998 ident: ref18 article-title: First recorded outbreak of yellow fever in Kenya, 1992–1993. I. Epidemiologic investigations publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1998.59.644 – ident: ref55 – volume: 6 start-page: 461 year: 1978 ident: ref49 article-title: Estimating the dimension of a model publication-title: Ann Stat doi: 10.1214/aos/1176344136 – volume: 11 start-page: 622 year: 2011 ident: ref11 article-title: The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70147-5 – ident: ref42 – ident: ref21 – volume: 41 start-page: 391 year: 2004 ident: ref2 article-title: Yellow fever: the recurring plague publication-title: Crit Rev Clin Lab Sci doi: 10.1080/10408360490497474 – volume: 66 start-page: 849 year: 2000 ident: ref37 article-title: LandScan: a global population database for estimating populations at risk publication-title: Photogramm Eng Rem S – ident: ref46 doi: 10.1201/b10905 – volume: 92 start-page: 333 year: 1999 ident: ref51 article-title: [Reemergence of yellow fever in West Africa: lessons from the past, advocacy for a control program] publication-title: Bulletin de la Société de pathologie exotique – volume: 9 start-page: 1 year: 2011 ident: ref8 article-title: Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections publication-title: Population Health Metrics doi: 10.1186/1478-7954-9-1 – volume: 25 start-page: 1965 year: 2005 ident: ref45 article-title: Very high resolution interpolated climate surfaces for global land areas publication-title: Int J Climatol doi: 10.1002/joc.1276 – ident: ref35 – volume: 31 start-page: B61 year: 2013 ident: ref9 article-title: The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance publication-title: Vaccine doi: 10.1016/j.vaccine.2012.11.035 – ident: ref14 |
| SSID | ssj0029090 |
| Score | 2.5554228 |
| Snippet | Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible... Background: Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is... Please see later in the article for the Editors' Summary. Neil Ferguson and colleagues estimate the disease burden of yellow fever in Africa, as well as the impact of mass vaccination campaigns. Please see later in... Neil Ferguson and colleagues estimate the disease burden of yellow fever in Africa, as well as the impact of mass vaccination campaigns. Please see later in... BackgroundYellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is... Background Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e1001638 |
| SubjectTerms | Africa Africa - epidemiology Alliances Bayes Theorem Biology and Life Sciences Cause of Death Cost of Illness Disease Disease Outbreaks - prevention & control Epidemics Estimates Fever Flavivirus Geography Humans Immunization Infections Management Mass Vaccination Medical research Medicine and Health Sciences Methods Prevention Regression Analysis Sensitivity analysis Seroepidemiologic Studies Social aspects Tropical diseases Vaccination Vaccines Yellow fever Yellow Fever - epidemiology Yellow Fever - mortality Yellow Fever - prevention & control Yellow Fever - transmission |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQHhAXRHk1bQGDEJxC83Acm1tBrApSiwQUlZPlOPZSUZIVuwsSv54Z21ltUEV74Jp8yWpnxvPIeD4T8tSUNm-lLtJCOihQrGtSzQo838TluoEK2jocTj465ocn7N1pdbpx1BfuCQv0wEFw-1wLCa9oWaEly2wlBdiYlE7nmkN0suh9IeYNxVQstWTmv64g_1iaF3Udh-bKOt-POnoxh2jjGYg4zqZsBCXP3b_20JP5eb-4KP38exflRlia3iI3Yz5JD8L_2CLXbHebXD-KHfM75PcX7K78olMLNkvPOhoOBnpJkV0Ds9VuRiEHpI0fZ6C9o7FlQ3XX0jBDiVe_Q5JNf2oDb_W6pDiXQvvVEkpq_c2DwZgHT0px4-ldcjJ98-n1YRrPW0gN5GFL8HvMCuHKAlu6wkmtKwaKLC23Ijey0pZnzonGVCAzBnowWZOLtoTg10oOir1HJl3f2W1CNSsbKBQt11DfCZ012khsWFrZyrriZULKQeDKRDJyPBPjXPkOWw1FSZCfQjWpqKaEpOun5oGM4xL8K9TlGotU2v4CGJiKBqYuM7CEPEJLUGEude0Q1EEpkEkox5954hFIp9Hhfp2ZXi0W6u37z1cAfTy-CujDCPQ8glwPMjM6DlKA5JHLa4R8NkLOApP5RcC9ERBcjBnd3sZVMMh4oSBMcuwpc5mQx8PKUPgUbtnrbL9CDGT2AtJ58S8Mcithaz4h98NqWisL7Abz1SIh9WidjbQ5vtOdffUE6QzHqaty53-of5fcgByZhT2ue2Sy_LGyDyAPXTYPvcv5A6dWg5Q priority: 102 providerName: Directory of Open Access Journals |
| Title | Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24800812 https://www.proquest.com/docview/1522681128 https://www.proquest.com/docview/1534824605 https://pubmed.ncbi.nlm.nih.gov/PMC4011853 https://doaj.org/article/6a894efd42a940e59857899fa1a6181e http://dx.doi.org/10.1371/journal.pmed.1001638 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe2TkK8IL4XGMUgBE-ZmsRJbCSENrRpgFpgMFSeLCexy0RJSj_4-uu5c5yIoAJ96UP6S6reh32X8_2OkAd5pINCqNAPhYEERZvMVyzE-SYmUBlk0Npgc_JwlJycsRfjeLxFmpmtToCLtakdzpM6m0_3v3_58RQc_omd2pAGzU37M9g_LKcQ2NQ22YG9KUVXHbK2rhCKgX3rgrxkfhCmqWum-9tTOpuV5fRvV-7ebFot1oWlf56u_G27Or5MLrk4kx7UhnGFbOnyKrkwdJX0a-TnB6y6fKNGgy3T85LWA4MeU2TdwCi2nFCIDWlm2xxoZagr5VBVFrTurcSrnyH4pl9VDk-1OqbYr0Kr1RJSbfXJgsHImxWW4oHU6-Ts-OjdsxPfzWHwc4jPlrAeMs25iUIs9XIjlIoZKDjSieZBLmKlk4ExPMtjkBnjcZoPsoAXEWyKhUhA4TdIr6xKvUuoYlEGCaROFOR9XA0ylQssZGpRiDROIo9EjcBl7kjKcVbGVNrKWwrJSi0_iWqSTk0e8du7ZjVJx3_wh6jLFosU2_ZCNZ9I57EyUVyA7RYsVIINdCzgj0FyalSgEgiLtEfuoiXIul-1XSjkQcSRYSjAn7lvEUizUeI5nolaLRby-av3G4DejjYBnXZAjxzIVCCzXLkGC5A8cnx1kA87yEnNcL4OuNcBwtKTd77eRS9oZLyQsH0mWGtOhEfuNZ4h8S48ylfqaoUYiPg5hPn8XxjkXMKSvUdu1t7UKgvsBuPY0CNpx8862ux-U55_tMTpDNus4-jWJtK8TS5CbMzqs617pLecr_QdiD-XWZ9sp-O0T3YOj0avT_v2LQ58vnzD-3ax-QVmV4fZ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Yellow+fever+in+Africa%3A+estimating+the+burden+of+disease+and+impact+of+mass+vaccination+from+outbreak+and+serological+data&rft.jtitle=PLoS+medicine&rft.au=Garske%2C+Tini&rft.au=Van+Kerkhove%2C+Maria+D&rft.au=Yactayo%2C+Sergio&rft.au=Ronveaux%2C+Olivier&rft.date=2014-05-01&rft.pub=Public+Library+of+Science&rft.issn=1549-1277&rft.volume=11&rft.issue=5&rft_id=info:doi/10.1371%2Fjournal.pmed.1001638&rft.externalDBID=ISR&rft.externalDocID=A382807138 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |